File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s11010-024-05064-3
- Scopus: eid_2-s2.0-85200167695
- WOS: WOS:001281336600001
- Find via

Supplementary
- Citations:
- Appears in Collections:
Article: Single-cell atlas profiling revealed cellular characteristics and dynamic changes after PD-1 blockade therapy of brain metastases from laryngeal squamous cell carcinoma
| Title | Single-cell atlas profiling revealed cellular characteristics and dynamic changes after PD-1 blockade therapy of brain metastases from laryngeal squamous cell carcinoma |
|---|---|
| Authors | |
| Keywords | Brain metastasis Immunosuppressive microenvironment Laryngeal squamous cell carcinoma PD-1 blockade Single‐cell RNA sequencing Tumor heterogeneity |
| Issue Date | 1-Aug-2024 |
| Publisher | Springer |
| Citation | Molecular and Cellular Biochemistry, 2024 How to Cite? |
| Abstract | Brain metastasis (BM) in laryngeal squamous cell carcinoma (LSCC) is uncommon but prognosis is poor. Anti-PD-1 immunotherapy benefits some advanced LSCC cases, yet its efficiency is limited by tumor complexity. We analyzed paired metastatic tumor samples from before and after immunotherapy using single-cell RNA sequencing (scRNA-seq), along with a primary LSCC dataset and bulk RNA sequencing. This identified changes post-immunotherapy and revealed differences in single-cell transcriptomes among LSCC, primBM, and neoBM. Our findings show that anti-PD-1 treatment suppresses metastasis-promoting pathways like VEGF and EMT in cancer cells, and alters immune cell functions. Notably, it upregulates T cell activation, leading to CD8 T cell exhaustion from excess heat shock proteins, notably HSPA8. However, CD8 T cell cytotoxic functions improve post-treatment. In myeloid cells, anti-PD-1 therapy enhances antigen presentation and promotes a proinflammatory shift post-metastasis. Additionally, NUPR1 is linked to BM in LSCC, and NEAT1 is a potential metastatic cancer cell cycle participant. Our study provides insights into cancer heterogeneity and the impact of PD-1 immunotherapy on metastasis, aiding precise diagnosis and prognosis. |
| Persistent Identifier | http://hdl.handle.net/10722/345921 |
| ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 0.901 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Zou, Yunzhi | - |
| dc.contributor.author | Duan, Hao | - |
| dc.contributor.author | Deng, Zekun | - |
| dc.contributor.author | Xiang, Rong | - |
| dc.contributor.author | Zhao, Jixiang | - |
| dc.contributor.author | Zhang, Zhenhua | - |
| dc.contributor.author | Hu, Wanming | - |
| dc.contributor.author | Yang, Yuanzhong | - |
| dc.contributor.author | Yan, Zeming | - |
| dc.contributor.author | Wen, Shujuan | - |
| dc.contributor.author | Liu, Zexian | - |
| dc.contributor.author | Zhang, Gao | - |
| dc.contributor.author | Mou, Yonggao | - |
| dc.contributor.author | Li, Depei | - |
| dc.contributor.author | Jiang, Xiaobing | - |
| dc.date.accessioned | 2024-09-04T07:06:28Z | - |
| dc.date.available | 2024-09-04T07:06:28Z | - |
| dc.date.issued | 2024-08-01 | - |
| dc.identifier.citation | Molecular and Cellular Biochemistry, 2024 | - |
| dc.identifier.issn | 0300-8177 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/345921 | - |
| dc.description.abstract | <p>Brain metastasis (BM) in laryngeal squamous cell carcinoma (LSCC) is uncommon but prognosis is poor. Anti-PD-1 immunotherapy benefits some advanced LSCC cases, yet its efficiency is limited by tumor complexity. We analyzed paired metastatic tumor samples from before and after immunotherapy using single-cell RNA sequencing (scRNA-seq), along with a primary LSCC dataset and bulk RNA sequencing. This identified changes post-immunotherapy and revealed differences in single-cell transcriptomes among LSCC, primBM, and neoBM. Our findings show that anti-PD-1 treatment suppresses metastasis-promoting pathways like VEGF and EMT in cancer cells, and alters immune cell functions. Notably, it upregulates T cell activation, leading to CD8 T cell exhaustion from excess heat shock proteins, notably HSPA8. However, CD8 T cell cytotoxic functions improve post-treatment. In myeloid cells, anti-PD-1 therapy enhances antigen presentation and promotes a proinflammatory shift post-metastasis. Additionally, NUPR1 is linked to BM in LSCC, and NEAT1 is a potential metastatic cancer cell cycle participant. Our study provides insights into cancer heterogeneity and the impact of PD-1 immunotherapy on metastasis, aiding precise diagnosis and prognosis.</p> | - |
| dc.language | eng | - |
| dc.publisher | Springer | - |
| dc.relation.ispartof | Molecular and Cellular Biochemistry | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | Brain metastasis | - |
| dc.subject | Immunosuppressive microenvironment | - |
| dc.subject | Laryngeal squamous cell carcinoma | - |
| dc.subject | PD-1 blockade | - |
| dc.subject | Single‐cell RNA sequencing | - |
| dc.subject | Tumor heterogeneity | - |
| dc.title | Single-cell atlas profiling revealed cellular characteristics and dynamic changes after PD-1 blockade therapy of brain metastases from laryngeal squamous cell carcinoma | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1007/s11010-024-05064-3 | - |
| dc.identifier.scopus | eid_2-s2.0-85200167695 | - |
| dc.identifier.eissn | 1573-4919 | - |
| dc.identifier.isi | WOS:001281336600001 | - |
| dc.identifier.issnl | 0300-8177 | - |
